Black Diamond Therapeutics reports Q4 EPS (28c), consensus (31c)

Black Diamond ended 2024 with approximately $98.6M in cash, cash equivalents, and investments compared to $131.4M as of December 31, 2023. Net cash used in operations was $62.3M for the year ended December 31, 2024 compared to $66.7M for the year ended December 31, 2023.”We continue to focus on advancing BDTX-1535 for the treatment of patients with EGFRm NSCLC and providing a clinical update on our Phase 2 trial for newly diagnosed patients in the second quarter of 2025,” said Mark Velleca, president and CEO of Black Diamond Therapeutics (BDTX). “We also look forward to the expansion in the first quarter of 2025 of the investigator sponsored window of opportunity trial of BDTX-1535 into newly diagnosed glioblastoma patients with EGFR aberrations, an area of high unmet medical need.”